Kang J, et al. - Researchers compared the efficacies of nab-paclitaxel plus gemcitabine (AG) and FOLFIRINOX as therapeutic options for patients presenting with metastatic pancreatic cancer (mPC) in daily practice setting. Progression-free survival (PFS) and overall survival (OS) was analyzed among mPC patients who received AG or FOLFIRINOX as first-line treatment. In daily practice setting, efficacy outcomes provided by AG or FOLFIRINOX were comparable. In patients with peritoneal metastasis, comorbid medical conditions or old age, AG might be preferentially considered.